Neonc Technologies Holdings, Inc. NTHI
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Neonc Technologies Holdings, Inc. (NTHI) is a healthcare company listed in the US with a market value of about $142M. In fiscal year 2025 it had revenue of $39990 and net income of -$62M, a net margin of -155404.4%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
About Neonc Technologies
Neonc Technologies is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 2 years in our data. It spends 9098% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | 2025 | 2024 |
|---|---|---|
| Revenue | $39990 | $83000 |
| Net income | -$62M | -$12M |
| Free cash flow | -$21M | — |
| EPS (diluted) | $-3.20 | $-0.69 |
| Net margin | -155400.0% | -14335.5% |
| ROIC | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $17.00, 246% above the current price; targets range from $13.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.24 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Neonc Technologies pay a dividend?
Not currently.
Is Neonc Technologies a good stock to buy?
We do not give buy or sell advice. Neonc Technologies scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.